Home | Looking for something? Sign In | New here? Sign Up | Log out
Showing posts with label Transplants. Show all posts
Showing posts with label Transplants. Show all posts

Tuesday, May 3, 2011

Taking Blood From Fukushima Radiation Workers To Prepare For Future Stem Cell Transplants In Case They Are Exposed To High Doses Of Radiation

Tuesday, May 3, 2011
0 comments


In Correspondence published Online First and an upcoming Lancet, Japanese experts suggest that blood products be taken from workers dealing with the ailing Fukushima Nuclear Facility-so that, should they accidently be exposed to high and health-damaging doses of radiation during the clean-up operation, they will be able to receive treatment by undergoing stem cell transplanation using their own cells (autologous transplant). The Correspondence authors are represented by Dr Shuichi Taniguchi, Toranomon Hospital, Tokyo, Japan, and Dr Tetsuya Tanimoto, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.

The authors say: "The danger of a future accidental radiation exposure is not passed, since there has been a series of serious aftershocks even [during] this April."


Generally, rapidly dividing cells, such as intestinal-tract cells, reproductive germ cells essential for fertility, and haemopoietic cells, are most vulnerable to radiation, which can depress bone marrow from a dose of about 2 Gy or higher. Haemopoietic cells are the precursor stem cells that later become a wide range of different blood cells in the body.


In previous nuclear disasters and accidents, allogeneic stem-cell transplantation (ie stem cells from a donor) has been used, But this has major limitations, such as time-consuming donor searching, graft failure, graft-versus-host disease (GVHD), or profound immune suppression after transplantation.


Instead of this, the Japanese call for collection of the peripheral blood stem cells (PBSC) of the workers themselves so that they could have future transplants should the need arise. This technique has several advantages over allogeneic transplantation; it does not cause GVHD, and does not require immunosuppressant drugs that make radiation victims even more vulnerable to infection. Further, the technique can more rapidly restore normal haemopoietic functionality in the body, the safety of the collection method is proven, and the cells are easy to freeze and store. Finally, it could be used to treat future leukaemia (a known possibility of radiation exposure) as well as bone marrow defects. But the authors also acknowledge autologous transplant is not perfect since it can rescue injury of bone marrow only and not other tissues, such as gastrointestinal tract, skin, or lung.


The authors say that 107 transplant teams are standing by in Japan to collect and store haemopoietic stem cells from the workers who are striving to restrain the radiation, and more than 50 hospitals in Europe have agreed to help the workers if required. But the Nuclear Safety Commission of Japan is resisting the plan, due to the "physical and psychological burden for nuclear workers", and there being "no consensus among international authoritative bodies, and no sufficient agreement among the Japanese public."


Tanimoto, Taniguchi and colleagues add: "The most important mission is to save the nuclear workers' lives and to protect the local communities. Such an approach would be the industry's best defence: if a fatal accident happened to the nuclear workers, the nuclear power industry of Japan would collapse."


They conclude: "The process to completely shut down the reactors in Fukushima is expected to take years. The risk of accidental radiation exposure will thus accumulate for the nuclear workers and banking of their autologous PBSCs will become increasingly important. A judgment of right or wrong on this scheme must be determined from the standpoint of the nuclear workers and their families, not from a point of view of cost-benefit balance in ordinary times. Toranomon Hospital in Tokyo is ready to harvest and bank autologous PBSCs for the nuclear workers upon request."


Source
The Lancet


read more

Wednesday, April 27, 2011

Long-Term Studies Find Enhanced Cord Blood Stem Cell Transplants To Be Safe

Wednesday, April 27, 2011
0 comments


Main Category: Stem Cell Research
Also Included In: Transplants / Organ Donations
Article Date: 19 Apr 2011 - 2:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
An innovative experimental treatment for boosting the effectiveness of stem-cell transplants with umbilical cord blood has a favorable safety profile in long-term animal studies, report scientists from Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center (BIDMC), and Children's Hospital Boston (CHB).

Analysis of long-term safety testing in nonhuman primates, published online by the journal Cell Stem Cell, revealed that, after one year following transplant, umbilical cord blood units treated with a signaling molecule called 16,16-dimethyl PGE2 reconstituted all the normal types of blood cells, and none of the animals receiving treated cord blood units developed cancer. Wolfram Goessling, MD, PhD, of Dana-Farber and Brigham and Women's Hospital, is the first author of the paper, and Trista North, PhD, of BIDMC is the senior author.

The results of long-term safety studies in mice were previously submitted to the Food and Drug Administration to gain permission for a Phase 1 clinical trial under an Investigational New Drug (IND) application. Principal investigator, Corey Cutler, MD, a Dana-Farber transplant specialist, initiated the trial in 2009 at Dana-Farber and the Massachusetts General Hospital. The IND is sponsored by Fate Therapeutics, Inc. of San Diego.

Goessling and North were post-doctoral fellows in the laboratory of co-author Leonard Zon, MD, a stem cell researcher at CHB and a scientific founder of Fate Therapeutics, when they hit upon 16,16-dimethyl PGE2 while looking for compounds that could regulate the production of hematopoietic stem cells. The initial testing made use of zebra fish models. Goessling commented that "this is the first time a compound discovered in zebra fish has received a nod from the FDA for a clinical trial."

One of the limitations of cord blood as a transplant source is the cells engraft, or "take," in the recipient's bone marrow more slowly than matched donor cells form bone marrow. In addition, there is a higher failure rate for cord blood transplants. Thus there is a need for ways to improve the speed and quality of cord blood transplantation.

Notes:

The research was supported by funding from the Harvard Stem Cell Institute, the National Institutes of Health, and the Howard Hughes Medical Institute.

The other authors are Michael Dovey, PhD, and James M. Harris, BIDMC; Xiao Guan, PhD, and Thorsten Schlaeger, PhD, CHB; Joseph Stegner and Myriam Armant, PhD, Center for Human Cell Therapy, Immune Disease Institute, Boston; Ping Jin, PhD, and David Stroncek, MD, National Institutes of Health, Bethesda, Md.; Naoya Uchida, MD, and John F. Tisdale, MD, National Heart, Lung, and Blood Institute/National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md.; Robyn S. Allen, Robert E. Donahue, VMD, Mark E. Metzger, and Aylin C. Bonifacino, National Heart, Lung, and Blood Institute, Bethesda, Md.

Source:
Bill Schaller
Dana-Farber Cancer Institute

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.




View the original article here

<

read more

Friday, April 15, 2011

Pig Stem Cell Transplants: The Key To Future Research Into Retina Treatment

Friday, April 15, 2011
0 comments


A team of American and Chinese scientists studying the role of stem cells in repairing damaged retina tissue have found that pigs represent an effective proxy species to research treatments for humans. The study, published in Stem Cells, demonstrates how cells can be isolated and transplanted between pigs, overcoming a key barrier to the research.

Treatments to repair the human retina following degenerative diseases remain a challenge for medical science. Unlike species of lower vertebrates the human retina lacks a regenerative pathway meaning that research has focused on cell transplantation.


"The retina is the light sensitive tissue surrounding the inner surface of the eye. Its outer layer is made up of rods and cone photoreceptor cells which convert light signals," said lead author Douglas Dean from the University of Louisville. "Traditionally transplant studies have focused on mice and other rodents because of the variety of genetic material they represent, however mouse retina tissue is rod dominant, which is significantly different to the human eye."


Dr Dean's team turned their attention to pigs because, as with humans, the swine eye contains a cone dominant central visual streak, making it a closer anatomical and physiological match.


"Studies into swine models have been hampered in the past," said Dean, "because the induced pluripotent stem cells (iPSCs) needed for such transplants have not been isolated from pigs, while their compatibility with a host's photoreceptor cells had not been demonstrated."


Dr Dean's team gathered iPSCs from swine skin fibroblasts and demonstrated that these cells differentiated in culture and could be integrated with the cells of a second pig's retina.


While only a small section of the retina was transplanted for this study the results could open a new avenue of research into degenerative conditions as researchers have a more effective human proxy species to work with.


"Our results demonstrate that swine stem cells can be integrated into a damaged swine neural retina," concluded Dean. "This research now lays a foundation for future studies of retinal stem cell transplantation in a swine model."


Full citation: Zhou. L, Wang. W, Liu. Y, Fernandez de Castro. J, Ezashi. T, Telugu. B, Roberts. M, Kaplan. H, Dean. D, "Differentiation of Swine iPSC into Rod Photoreceptors and Their Integration into the Retina", Stem Cells, Wiley-Blackwell, DOI: 10.1002/stem.637


Source:
Alpha Med Press
Wiley-Blackwell


 


read more
 

Popular Posts